Dr. Syed's interview with Dr. Hertz was compassionate and informative, and if you're reading this, Dr. Hertz, many thanks!! I would like to comment on the NIH study. (1) By being in medRxiv, *optimally* the paper will receive thoughtful review from the peer and general community. Hopefully with feedback, it will undergo the step of peer review for a medical journal as well, to receive wider attention from the medical and research community. (2) The purpose of the study was to investigate plausibility that neurological consequences of SARS-CoV-2 vaccination are immune-mediated, and the authors provide several lines of evidence to support that. (3) It does *not* appear to be the case that all patients recovered or improved. While 3 patients who had not recovered improved after intravenous gamma-globulin, Table 4 shows that many patients didn't recover or only partly recovered (I believe to get to the exact number, you might have to look in the first 3 rows--that adds to 23 patients; the 4th row for IVIG is 3 of the patients from the top 3 rows--confusing!!). Partial or total recovery with immune-directed therapy supported the study's hypothesis (immune dysfunction contributes to post-vaccine neurological symptoms)
Dr. Syed's interview with Dr. Hertz was compassionate and informative, and if you're reading this, Dr. Hertz, many thanks!! I would like to comment on the NIH study. (1) By being in medRxiv, *optimally* the paper will receive thoughtful review from the peer and general community. Hopefully with feedback, it will undergo the step of peer review for a medical journal as well, to receive wider attention from the medical and research community. (2) The purpose of the study was to investigate plausibility that neurological consequences of SARS-CoV-2 vaccination are immune-mediated, and the authors provide several lines of evidence to support that. (3) It does *not* appear to be the case that all patients recovered or improved. While 3 patients who had not recovered improved after intravenous gamma-globulin, Table 4 shows that many patients didn't recover or only partly recovered (I believe to get to the exact number, you might have to look in the first 3 rows--that adds to 23 patients; the 4th row for IVIG is 3 of the patients from the top 3 rows--confusing!!). Partial or total recovery with immune-directed therapy supported the study's hypothesis (immune dysfunction contributes to post-vaccine neurological symptoms)